Roche Commits Up To $1bn For Blueprint's Immunokinase Inhibitors

When Blueprint Medicines Corp. sought a partner to help advance its kinase inhibitors with the potential to boost immune responses to cancer, the company came up with a short list of ideal big pharma collaborators and Roche rose to the top.